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Abstract
Prevalence and predictors of transmitted drug resistance (TDR),
defined as the presence of at least one WHO surveillance drug
resistance mutation (SDRM), were investigated in antiretroviral-
naı¨ve HIV-1-infected patients, with a genotypic resistance test
(GRT) performed £6 months before starting cART between
2000 and 2010. 3163 HIV-1 sequences were selected (69% sub-
type B). Overall, the prevalence of TDR was 12% (13.2% sub-
type B, 9% non-B). TDR significantly declined overall and for the
single drug classes. Older age independently predicted increased
odds of TDR, whereas a more recent GRT, a higher HIV-RNA
and C vs. B subtype predicted lower odds of TDR.
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Introduction
The introduction of combination antiretroviral therapy
(cART) has allowed us to obtain high rates [1–5] of success
in controlling the replication of HIV. In Italy, the prevalence
of TDR ranged from 5.9% to 15.1% in two studies between
1992 and 2007 [6,7]. We had analysed the temporal trends
and predictors of TDR in Italy in a previous study between
1996 and 2007 [8].
The present study aimed to extend the follow-up of our
previous work [8] and to evaluate possible predictors and
trends of TDR prevalence in the Italian population from
2000 to 2010.
Materials and methods
Sequences from HIV-1-infected, treatment-naı¨ve patients with
a GRT performed £6 months before starting cART from 2000
to 2010 were retrieved from the ARCA database (http://
www.hivarca.net 8) and from separate databases at the Catho-
lic University of Sacred Heart (CUSH) and at the University
Hospital ‘Spedali Civili’ of Brescia, Italy. For each patient, only
the first genotype was considered. We defined an ‘acute/
recent’ infection if the first HIV-positive test was obtained
within 1–18 months since the last available negative test or if a
primary HIV infection (PHI) could be demonstrated and a
‘non-acute/non-recent’ infection when the time between an
HIV-negative and a subsequent positive test was longer than
previously stated or when no negative test was available.
Transmitted drug resistance was defined as the detection of
at least one mutation among those indicated in the WHO-rec-
ommended SDRM list updated in 2009 (available at: http://hiv-
db.stanford.edu/pages/WHOResistanceList.html) [9].
HIV-1 subtyping was automatically performed upon
sequence upload by BLAST [8].
The changes in the prevalence of TDR per calendar year
were evaluated with v2 test for trend; logistic regression analy-
sis was used in order to evaluate the predictors of TDR.
Results
A total of 3163 (65% from ARCA, 14% from CUSH and 21%
from Brescia) protease and reverse transcriptase sequences
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obtained between 2000 and 2010 from treatment-naive
patients were analysed. Two hundred and twenty-six (7%) of
3163 patients were diagnosed with an acute or recent HIV
infection.
The evolution of patients’ characteristics over time is
shown in Table 1.
The overall prevalence of any drug resistance mutation in
patients with ‘non-acute/non-recent’ infection was 11.7%;
NRTI, NNRTI and major PI resistance mutations were
detected in 7.4%, 5% and 2.9% of patients, respectively. The
prevalence of any drug resistance mutations was significantly
reduced in 2010 compared with 2000 (8.2% vs. 24.1%,
p <0.001). The proportion of patients presenting any major
IAS mutation associated with NRTI resistance, NNRTI
resistance and PI resistance in this subgroup is shown in
Fig. 1a.
The overall proportion of non-B strains increased from
18% in 2000 to 24% in 2010 (p <0.001); the prevalence of
unknown subtypes was also increased from 5% to 18%
(p <0.001) (see Fig. 1b). The CRF02_AG subtype showed an
increase from 3/62 (5%) to 10/169 (6%, p 0.67) and F1
increased from 3/62 (5%) to 8/169 (5%, p 0.81). Among Ital-
ian natives, 310/2224 (13%) carried non-B viral strains; the
prevalence of these subtypes increased over calendar years
(11% in 2000–2003, 14% in 2004–2007, 19% in 2008–2010;
overall p 0.01), peaking in 2009 (51/251, 25%).
The overall prevalence of subtype B HIV-1 strains was
69%. The prevalence of TDR was higher in B than in non-
B subtype (13% vs. 9%, p 0.002) carriers. The prevalence
of TDR in subtype B and non-B was 8% and 5% for
NRTIs (p 0.003), 6% and 3% for NNRTIs (p <0.001), and
3% each for PIs (p 0.94); the changes over calendar year
in the trends for B and non-B subtypes is shown in
Fig. 1(c,d).
In patients diagnosed with an acute or recent HIV infec-
tion from 2000 to 2010 the overall prevalence of any drug
resistance mutation was 14%; NRTI, NNRTI and major PI
resistance mutations were detected in 7%, 7% and 3% of
patients, respectively. Subtype B HIV-1 was detected in 185/
226 (82%) samples; the most frequently observed non-B sub-
type was F1 (5%).
At multivariable logistic regression analysis, older age inde-
pendently predicted higher odds of transmitted drug resis-
tance mutations. More recent calendar year, higher plasma
HIV-RNA and infection with non-subtype B strains indepen-
dently predicted reduced odds of TDR (see Table 2).
TABLE 1. Descriptive characteristics of general population and of patients among different quartiles
Total population
N = 3163
2000–2003
N = 398
2004–2007
N = 1793
2008–2010
N = 972
p-value
Median age (IQR) (years) 37 (30–43) 35 (30–41) 37 (30–43) 38 (31–46) 0.001
Male sex (%) 74 71 73 76 0.07
Median calendar year at genotyping (IQR) 2006 (2005–2008)
Risk factors
Heterosexual contacts (%) 40 38 27 40 0.80
Homosexual contacts (%) 26 25 27 26 0.93
Injecting drug use (%) 11 14 12 9 0.002
Other or unknown (%) 23 23 20 25 0.05
Country of birth
Italy (%) 81 61 70 78 <0.001
Sub-Saharan Africa (%) 8 4 8 8 0.007
Latin America and Caribbean (%) 5 5 4 3 0.30
Eastern Europe (%) 3 4 2 2 0.72
Other (%) 3 5 4 3 0.58
Patients followed at sites
Northern Italy (%) 46 45 54 41 <0.001
Central Italy (%) 50 50 37 36 <0.001
Southern Italy and islands (%) 4 5 9 23 <0.001
Subtype, n (%)
B 69 77 72 61 0.002
Non-B 22 18 23 24
Unknown 9 6 6 16
Distribution of non-B subtypes, %
F1 17.3 23.7 18.9 13.6
02_AG 15.8 15.1 19.5 11
C 14 14 13.6 14.4
G 6.2 5.4 8.3 13.7
Other (<5% each) 18.5 17.1 19.6 7.4
Unknown 28.2 24.7 20.1 39.9
VL median (IQR) (log copies/mL) 4.58 (4.04–5.15) 4.42 (3.89–5.12) 4.61 (4.06–5.16) 4.58 (4.04–5.16) 0.006
CD4 median (IQR) (cells/mm3) 357 (201–518) 361 (185–557) 360 (226–527) 342 (161–503) 0.02
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Discussion
This is an observational study aiming to analyse the preva-
lence of TDR in HIV-infected patients in three large Italian
cohorts. The declining trend in the prevalence of any TDR
mutation that we had observed [8] was confirmed until
2010.
We observed a significantly increased proportion of treat-
ment-naı¨ve patients carrying non-B subtype HIV-1 in the last
10 years. This confirms our previous observation reporting
an increased prevalence of non-subtype B strains over two
decades (1983–2006) in Brescia [10].
At multivariate analysis, we observed a lower risk of TDR
in patients tested for GRT in a more recent calendar year,
probably as an effect of the improvement in the management
of cART. The lower risk of TDR in patients with higher
baseline viral load could be related to the higher fitness of
wild-type HIV [11]. Finally, the lower prevalence of TDR in
non-B subtype-infected subjects is in line with the lower
exposure to cART in countries where these subtypes are
prevalent. We acknowledge that the surveillance list of resis-
tance mutations for non-B subtypes is still being completely
defined; however, we referred to the last available 2009 list
[9], where a considerable number of mutations were added
to those previously recognized.
The analysis of TDR in patients with acute or recent HIV
infection is of great interest but is limited by the low rates
of documented seroconversion or diagnosed PHIs.
The high proportion of patients with unknown duration of
HIV infection is an important confounder, but this is difficult
to overcome because in clinical practice the proportion of
patients with a recent negative test at the diagnosis of HIV
infection always represents a minority. Finally, a relevant part
of subtypes could not be determined, particularly in recent
years.
In conclusion, the prevalence of TDR is declining in our
multicentre cohort; this probably reflects the improvement
in the management and prescription of antiretroviral drugs
and the availability of new drugs.
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FIG. 1. Evolution of resistance (at least one major IAS mutation) by calendar year from 2000 to 2010 in naive patients with non-acute/non-
recent infection (a, n = 2937), evolution of the prevalence of B, non-B and unknown subtypes (b) and evolution of the prevalence of drug resis-
tance in B subtype (c) and in non-B subtypes (d). NRTI, nucleoside reverse transcriptase inhibitor; NNRTI, non-nucleoside reverse transcriptase
inhibitor; PI, protease inhibitor.
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